Patent · US Active

Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof

US10442811B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

Zhaozhong Ding · Shanghai, CN
Fei Sun · Shanghai, CN
Yinghu Hu · Shanghai, CN
Yilong Zhou · Shanghai, CN
Zheng Wang · 安丰镇, CN
Rui Zhao · Beijing, CN
Ling Yang · Lianyungang, CN

Key dates

Filing date	Feb 4, 2017
Grant date	Oct 15, 2019
Priority date	—
Expiry date	Feb 4, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.